Compass Therapeutics (CMPX) insider buying

Healthcare · Biotechnology · Market cap $173M

3 open-market purchases of CMPX by Compass Therapeutics's executives and directors since May 2025, worth $42,350 in total, from SEC Form 4 filings.

The most recent: Neil Lerner, Chief Accounting Officer bought $18,400 on October 1, 2026.

The biggest buyer over the period is Neil Lerner (Chief Accounting Officer): 2 purchases, $21,250.

By year

YearPurchasesValue
20262$21,250
20251$21,100

Biggest buyers

InsiderBuysValue
Neil Lerner
Chief Accounting Officer		2$21,250
Thomas J Schuetz
1$21,100

Every purchase

Newest first. From SEC Form 4 filings. Insider buying across the market.

DateInsiderSharesPriceValueFiling
Oct 1, 2026 Neil Lerner
Chief Accounting Officer		 20,000$0.92$18,400 Form 4
Sep 24, 2026 Neil Lerner
Chief Accounting Officer		 2,500$1.14$2,850 Form 4
May 27, 2025 Thomas J Schuetz
 10,000$2.11$21,100 Form 4
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CMPX.
Open CMPX in Investingly

Questions

Are Compass Therapeutics insiders buying the stock?

3 open-market purchases of CMPX by Compass Therapeutics's executives and directors since May 2025, worth $42,350 in total, from SEC Form 4 filings. The most recent: Neil Lerner, Chief Accounting Officer bought $18,400 on October 1, 2026.

What counts as insider buying here?

Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.

From Compass Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.